Saltar al contenido
PivotalWire
Jueves 15 oct 2026SEC · NASDAQ biomédico

Portada›Martes 23 de septiembre de 2025

Biomédicas del NASDAQ ante la SEC, martes 23 de septiembre de 2025

Los 22 documentos que 20 empresas del sector presentaron ante la SEC ese día, agrupados por tipo y con el enlace al original en EDGAR.

·

El día, bloque a bloque

¿Lo quieres en tu correo cada mañana, y solo de tus empresas? Crear una cuenta.

Por qué unas líneas van en color

Va en color lo que cambia el capital o avisa de un riesgo: las emisiones con precio (424B1, 424B2, 424B4 y 424B5), los 8-K con item 1.02, 1.03, 2.04, 3.01, 3.02 y 4.02, y cualquier documento en el que haya aparecido una frase vigilada, que va citada debajo. Lo demás va en tinta normal. Una cita marcada «por primera vez» es una frase que no estaba en el informe previo del mismo tipo de esa empresa. La etiqueta del formulario lleva a su explicación.

Emisiones y dilución

  1. CDIOCardio Diagnostics Holdings, Inc.424B3Prospecto suplementario o de reventaEDGAR
    En el documentoContrasplit de accionestexto original ▸…filed with the Securities and Exchange Commission (“SEC”) on March 20, 2025. Reverse Stock Split The Company held its annual meeting of stockholders on November 15, 2024, where the Company’s stockholders approved a reverse stock split at a ratio within a range of 1-for-5 and 1-for-40 and granted the Company’s Board of Directors the discretion to determine the timing and ratio of the split within such range. On April 10, 2025, the Company…
  2. DCOYDecoy Therapeutics Inc.S-1/ACapacidad de emisión registrada (enmienda)EDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…reserves. •The pendency of the Merger could have an adverse effect on the trading price of Salarius’ common stock and its business, financial condition and prospects. •Decoy’s financial condition raises substantial doubt regarding its ability to continue as a going concern. •Decoy has never generated revenue from product sales and all of Decoy’s product candidates are currently in the preclinical stage, and Decoy may continue to incur significant losses for the foreseeable…
    En el documentoAviso de incumplimiento de las reglas de cotizacióntexto original ▸…received notification from Nasdaq that the Hearings Panel had granted Salarius an additional extension to regain compliance with the Equity Standard by October 20, 2025. On September 4, 2025, Salarius received written notice from Nasdaq that it had regained compliance with the Minimum Bid Price Requirement by the required deadline. Nasdaq further notified Salarius that it will be subject to a Mandatory Panel Monitor for a period of one year from September 4, 2025. If, within that one-year monitoring…
    En el documentoContrasplit de accionestexto original ▸…Bid Price Requirement. However, pursuant to Nasdaq listing rule 5810(c)(3)(A)(iv), Salarius is not eligible for any compliance period specified in Nasdaq listing rule 5810(c)(3)(A) because Salarius has effected a reverse stock split during the prior one-year period. In addition, as previously disclosed, on March 26, 2025, Salarius received a letter from Nasdaq notifying Salarius that, based on the financial statements contained in…
    En el documentoPrograma de venta continua de acciones (ATM)texto original ▸…Decoy and their respective directors and executive officers may sell shares into the market, which could adversely affect the market price of shares of Salarius’ common stock. Salarius has previously entered into an At the Market Offering Agreement dated as of February 5, 2021, with the representative, pursuant to which, from time to time, Salarius may offer and sell shares of its common stock under an “at-the-market” offering program…
  3. NEUPNeuphoria Therapeutics Inc.424B5Nueva emisión de acciones con precioEDGAR
    En el documentoPrograma de venta continua de acciones (ATM)texto original ▸…unchanged. This Amendment is not complete without, and may only be delivered or utilized in connection with, the Prospectus Supplement, and any future amendments or supplements hereto or thereto. We have entered into an At The Market Offering Agreement, or the Sales Agreement, with H.C. Wainwright & Co., LLC, or Wainwright, dated November 18, 2024. Under this Sales Agreement, as updated by this Amendment, we may offer and sell common stock…
  4. LFCRLIFECORE BIOMEDICAL, INC. \DE\S-3Capacidad de emisión registradaEDGAR

Participaciones y control

  1. ALZNAlzamend Neuro, Inc.SC 13D/ACambio en participación significativaEDGAR
  2. CGTXCOGNITION THERAPEUTICS INCSC 13D/ACambio en participación significativaEDGAR
  3. JSPRJasper Therapeutics, Inc.SC 13D/ACambio en participación significativaEDGAR
  4. SLXNSilexion Therapeutics CorpSC 13D/ACambio en participación significativaEDGAR

Informes y hechos relevantes

  1. AGENAGENUS INC8-KOtros hechos relevantesEDGAR
  2. AYTUAYTU BIOPHARMA, INC8-KResultadosEDGAR
  3. AYTUAYTU BIOPHARMA, INC10-KInforme anualEDGAR
  4. BFRGBullFrog AI Holdings, Inc.8-KCambio de estatutosEDGAR
  5. BYSIBeyondSpring Inc.8-KNuevo acuerdo materialEDGAR
  6. INMInMed Pharmaceuticals Inc.10-KInforme anualEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…Canadian courts based upon the civil liability provisions of the Canadian securities laws or other laws of Canada. Risks Related to our Financial Position and Capital Needs Our operating losses have raised substantial doubt regarding our ability to continue as a going concern. Our operating losses raise substantial doubt about our ability to continue as a going concern. As a result, our independent registered public accounting firms included an explanatory paragraph in its…
    En el documentoContrasplit de accionestexto original ▸…Bid Price Rule for ten consecutive trading days as of the Requisite Compliance Date of December 2, 2024, and of other conditions stipulated by the Panel Determination Letter. On November 14, 2024, we effected the Reverse Stock Split of our issued and outstanding common shares, by a ratio of 20-to-1. Trading of our common shares on Nasdaq on a split-adjusted basis began as of November 14, 2024. We effected the Reverse Stock Split…
    En el documentoPrograma de venta continua de acciones (ATM)texto original ▸…announcement, and we shall be obligated to immediately notify the Investor of the termination of the Black Out Period. Amended At-the-Market Offering Agreement (‘ATM Amendment’) On June 27, 2024, the Company entered into an amendment (the “ATM Amendment”) to its At-the-Market Offering Agreement, dated April 7, 2022 (the “Original ATM Agreement” and together with the ATM Amendment, the “Amended ATM Agreement”), pursuant to which the Company may offer and sell Common Shares, from time…
  7. INMInMed Pharmaceuticals Inc.8-KOtros hechos relevantesEDGAR
  8. KRSAKorsana Biosciences, Inc.8-KNuevo acuerdo materialEDGAR
    En el documentoAcuerdo de licencia o colaboracióntexto original ▸…Company an exclusive worldwide license to develop and commercialize products using certain technology for the treatment of neuropsychiatric disorders, such as depression, in humans. Under the terms of the License Agreement, the Company will pay to MIT a nominal upfront payment, and MIT will be eligible to receive up to $4.4 million upon the achievement of certain development, regulatory and sales milestone payments. MIT will also receive tiered royalties in a range…
  9. NAIINATURAL ALTERNATIVES INTERNATIONAL INC10-KInforme anualEDGAR
  10. PTNPALATIN TECHNOLOGIES INC10-KInforme anualEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…limitation, the following are forward-looking statements: · our significant operating losses since our inception and our need to obtain additional financing has caused management to determine there is substantial doubt regarding our ability to continue as a going concern; · our ability to obtain additional financing on terms acceptable to us, or at all, including unavailability of funds or delays in receiving funds as a result of economic disruptions; · our expectation…
    En el documentoDebilidad material en el control internotexto original ▸…provide only reasonable assurance with respect to financial statement preparation and presentation. As previously disclosed in our Annual Report on Form 10-K for the year ended June 30, 2024, management identified a material weakness in control over accounting for complex financial instruments. During the year ended June 30, 2025, management implemented a number of measures to remediate this material weakness including enhanced polices…
  11. SCNXScienture Holdings, Inc.8-KNuevo acuerdo materialEDGAR
  12. SRRKScholar Rock Holding Corp8-KOtros hechos relevantesEDGAR

Juntas de accionistas

  1. ASBPAspire-Lakewood Holdings, Inc.DEF 14AConvocatoria de junta de accionistasEDGAR
  2. XCUREXICURE, INC.DEF 14AConvocatoria de junta de accionistasEDGAR

·

Esto mismo, cada mañana y solo de tus empresas. Sigue a las que te interesen y recibe en tu correo lo que presenten ante la SEC, en castellano. Crear una cuenta. ¿Ya tienes cuenta? Entrar.

Esto no son recomendaciones de inversión. Son hechos públicos verificables en su fuente. Lee siempre el documento original antes de decidir nada. Aviso legal.